Eledon Pharmaceuticals to Present at Jefferies Healthcare Conference
02 Junho 2023 - 9:00AM
Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today
announced that David-Alexandre C. Gros, M.D., Chief Executive
Officer, will present a company overview at the upcoming Jefferies
Healthcare Conference on Friday, June 9, 2023, at 9:00 a.m. ET.
To register in advance for the presentation webcast, sign up
here.
A webcast replay will be accessible following the live session
on the Events page of the Investors section on the Company’s
website
at https://ir.eledon.com/events-and-presentations/events.
About Eledon Pharmaceuticals and tegoprubart (formerly
AT-1501)
Eledon Pharmaceuticals is a clinical stage biotechnology company
using its immunology expertise in targeting the CD40 Ligand (CD40L,
also called CD154) pathway to develop therapies to protect
transplanted organs and prevent rejection, and to treat ALS. The
company’s lead compound in development is tegoprubart, an
anti-CD40L antibody with high affinity for CD40 Ligand, a
well-validated biological target with broad therapeutic potential.
Eledon is headquartered in Irvine, California. For more
information, please visit the company’s website at
www.eledon.com.
Follow Eledon Pharmaceuticals on social media: LinkedIn;
Twitter
Investor Contact:
Stephen JasperGilmartin Group(858) 525
2047stephen@gilmartinir.com
Source: Eledon Pharmaceuticals
Eledon Pharmaceuticals (NASDAQ:ELDN)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Eledon Pharmaceuticals (NASDAQ:ELDN)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024